Barchart Research What to Expect from RDY Earnings RDY Generated May 7, 2026 Current Price $13.43 EPS Estimate $$0.09 Consensus Rating Moderate Sell Average Move 2.59% Dr. Reddy's Reports Tuesday With...
Dr. Reddy’s becomes the first company to receive marketing authorization for generic Semaglutide Injection in Canada The market authorization was granted...
Following the submission in December 2025, USFDA has accepted Dr. Reddy’s 351(k) Biologics License Application (BLA) for Proposed Interchangeable biosimilar Abatacept, DRL_AB (IV for Infusion) ...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of over-the-counter (OTC) Olopatadine...
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced initial clinical results from 1 st two cohorts...
/Zoetis%20Inc%20logo%20on%20phone-by%20viewimage%20via%20Shutterstock.jpg)
Zoetis's shares are trailing the broader Dow Jones index, yet analysts still project upside, signaling confidence in the company’s long-term recovery potential.
Aurigene Oncology Limited , a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced that it will present new data from its proprietary Targeted Protein...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Dr Reddy’s...
FDA acceptance enables initiation of a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of COYA 302 in patients with ALS
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2025. The information mentioned...